Enanta Pharmaceuticals’ Partner AbbVie Receives European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/23/2026

1. DHR
2. USO
3. NVDA
4. SPY
5. AMD
6. SMCI
7. NOW
8. GM
9. IBM
10. EFX

Go back to Enanta Pharmaceuticals’ Partner AbbVie Receives European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus
ENANTA PHARM (NASDAQ: ENTA) Delayed: 13.06 -0.36 (2.68%)
Previous Close $13.42    52 Week High $34.49 
Open $13.36    52 Week Low $20.39 
Day High $13.82    P/E N/A 
Day Low $13.01    EPS $-3.18 
Volume 153,951